15/120
0.6 / 5 stars
All 120 Win/Lose results shown below
NAMS Roast Me summary
NewAmsterdam Pharma Co N.V. (NAMS). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseNAMS / S&P 5.87% / 15.20% |
LoseNAMS / S&P -88.87% / 15.00% |
LoseNAMS / S&P NAMS unavailable / 50.40% |
| 2026-Q10/3 |
LoseNAMS / S&P -8.75% / -4.33% |
LoseNAMS / S&P -52.13% / 11.30% |
LoseNAMS / S&P NAMS unavailable / 27.70% |
| 2025-Q41/3 |
WinNAMS / S&P 23.35% / 2.65% |
LoseNAMS / S&P -50.61% / 9.00% |
LoseNAMS / S&P NAMS unavailable / 13.40% |
| 2025-Q32/3 |
WinNAMS / S&P 57.04% / 8.12% |
WinNAMS / S&P 4.91% / 4.61% |
LoseNAMS / S&P NAMS unavailable / 13.45% |
| 2025-Q21/3 |
LoseNAMS / S&P -11.53% / 10.94% |
WinNAMS / S&P 762.15% / 4.83% |
LoseNAMS / S&P NAMS unavailable / 10.63% |
| 2025-Q11/3 |
LoseNAMS / S&P -20.35% / -4.27% |
WinNAMS / S&P 586.97% / 4.98% |
LoseNAMS / S&P NAMS unavailable / 10.57% |
| 2024-Q42/3 |
WinNAMS / S&P 54.82% / 2.41% |
WinNAMS / S&P 223.37% / 5.25% |
LoseNAMS / S&P NAMS unavailable / 6.15% |
| 2024-Q30/3 |
LoseNAMS / S&P -13.59% / 5.89% |
LoseNAMS / S&P NAMS unavailable / 5.89% |
LoseNAMS / S&P NAMS unavailable / 6.11% |
| 2024-Q20/3 |
LoseNAMS / S&P -18.77% / 4.28% |
LoseNAMS / S&P NAMS unavailable / 5.38% |
LoseNAMS / S&P NAMS unavailable / 5.12% |
| 2024-Q11/3 |
WinNAMS / S&P 111.73% / 10.56% |
LoseNAMS / S&P NAMS unavailable / 5.71% |
LoseNAMS / S&P NAMS unavailable / 5.59% |
| 2023-Q41/3 |
WinNAMS / S&P 20.76% / 11.69% |
LoseNAMS / S&P -86.28% / 6.81% |
LoseNAMS / S&P NAMS unavailable / 7.78% |
| 2023-Q30/3 |
LoseNAMS / S&P -22.20% / -3.27% |
LoseNAMS / S&P NAMS unavailable / 7.52% |
LoseNAMS / S&P NAMS unavailable / -5.03% |
| 2023-Q20/3 |
LoseNAMS / S&P -10.33% / 8.74% |
LoseNAMS / S&P NAMS unavailable / 9.50% |
LoseNAMS / S&P NAMS unavailable / -8.57% |
| 2023-Q11/3 |
WinNAMS / S&P 21.65% / 7.50% |
LoseNAMS / S&P NAMS unavailable / 10.77% |
LoseNAMS / S&P NAMS unavailable / -15.69% |
| 2022-Q41/3 |
WinNAMS / S&P 9.33% / 7.56% |
LoseNAMS / S&P NAMS unavailable / 11.88% |
LoseNAMS / S&P NAMS unavailable / -17.99% |
| 2022-Q31/3 |
WinNAMS / S&P 1.01% / -4.88% |
LoseNAMS / S&P NAMS unavailable / 13.47% |
LoseNAMS / S&P NAMS unavailable / -1.41% |
| 2022-Q21/3 |
WinNAMS / S&P 0.41% / -16.10% |
LoseNAMS / S&P NAMS unavailable / 13.71% |
LoseNAMS / S&P NAMS unavailable / 11.04% |
| 2022-Q11/3 |
WinNAMS / S&P 0.82% / -4.60% |
LoseNAMS / S&P NAMS unavailable / 15.97% |
LoseNAMS / S&P NAMS unavailable / 42.23% |
| 2021-Q40/3 |
LoseNAMS / S&P -0.71% / 11.03% |
LoseNAMS / S&P NAMS unavailable / 15.00% |
LoseNAMS / S&P NAMS unavailable / 96.40% |
| 2021-Q31/3 |
WinNAMS / S&P 0.61% / 0.58% |
LoseNAMS / S&P NAMS unavailable / 10.77% |
LoseNAMS / S&P NAMS unavailable / 69.42% |
| 2021-Q20/3 |
LoseNAMS / S&P -2.01% / 8.55% |
LoseNAMS / S&P NAMS unavailable / 6.58% |
LoseNAMS / S&P NAMS unavailable / 51.81% |
| 2021-Q10/3 |
LoseNAMS / S&P NAMS unavailable / 6.17% |
LoseNAMS / S&P NAMS unavailable / -1.06% |
LoseNAMS / S&P NAMS unavailable / 7.39% |
| 2020-Q40/3 |
LoseNAMS / S&P NAMS unavailable / 12.15% |
LoseNAMS / S&P NAMS unavailable / -3.72% |
LoseNAMS / S&P NAMS unavailable / -33.42% |
| 2020-Q30/3 |
LoseNAMS / S&P NAMS unavailable / 8.93% |
LoseNAMS / S&P NAMS unavailable / -2.04% |
LoseNAMS / S&P NAMS unavailable / -27.10% |
| 2020-Q20/3 |
LoseNAMS / S&P NAMS unavailable / 20.54% |
LoseNAMS / S&P NAMS unavailable / -0.46% |
LoseNAMS / S&P NAMS unavailable / -27.11% |
| 2020-Q10/3 |
LoseNAMS / S&P NAMS unavailable / -19.60% |
LoseNAMS / S&P NAMS unavailable / 3.47% |
LoseNAMS / S&P NAMS unavailable / -14.75% |
| 2019-Q40/3 |
LoseNAMS / S&P NAMS unavailable / 9.07% |
LoseNAMS / S&P NAMS unavailable / 5.36% |
LoseNAMS / S&P NAMS unavailable / 2.99% |
| 2019-Q30/3 |
LoseNAMS / S&P NAMS unavailable / 1.70% |
LoseNAMS / S&P NAMS unavailable / 5.02% |
LoseNAMS / S&P NAMS unavailable / 0.21% |
| 2019-Q20/3 |
LoseNAMS / S&P NAMS unavailable / 4.30% |
LoseNAMS / S&P NAMS unavailable / 6.64% |
LoseNAMS / S&P NAMS unavailable / 8.65% |
| 2019-Q10/3 |
LoseNAMS / S&P NAMS unavailable / 13.65% |
LoseNAMS / S&P NAMS unavailable / 8.12% |
LoseNAMS / S&P NAMS unavailable / 14.29% |
| 2018-Q40/3 |
LoseNAMS / S&P NAMS unavailable / -13.52% |
LoseNAMS / S&P NAMS unavailable / 9.05% |
LoseNAMS / S&P NAMS unavailable / 18.23% |
| 2018-Q30/3 |
LoseNAMS / S&P NAMS unavailable / 7.71% |
LoseNAMS / S&P NAMS unavailable / 10.21% |
LoseNAMS / S&P NAMS unavailable / 19.06% |
| 2018-Q20/3 |
LoseNAMS / S&P NAMS unavailable / 3.43% |
LoseNAMS / S&P NAMS unavailable / 9.03% |
LoseNAMS / S&P NAMS unavailable / 14.46% |
| 2018-Q10/3 |
LoseNAMS / S&P NAMS unavailable / -0.76% |
LoseNAMS / S&P NAMS unavailable / 7.68% |
LoseNAMS / S&P NAMS unavailable / 12.46% |
| 2017-Q40/3 |
LoseNAMS / S&P NAMS unavailable / 6.64% |
LoseNAMS / S&P NAMS unavailable / 7.03% |
LoseNAMS / S&P NAMS unavailable / 13.82% |
| 2017-Q30/3 |
LoseNAMS / S&P NAMS unavailable / 4.48% |
LoseNAMS / S&P NAMS unavailable / 5.68% |
LoseNAMS / S&P NAMS unavailable / 17.57% |
| 2017-Q20/3 |
LoseNAMS / S&P NAMS unavailable / 3.09% |
LoseNAMS / S&P NAMS unavailable / 4.83% |
LoseNAMS / S&P NAMS unavailable / 17.74% |
| 2017-Q10/3 |
LoseNAMS / S&P NAMS unavailable / 6.07% |
LoseNAMS / S&P NAMS unavailable / 3.67% |
LoseNAMS / S&P NAMS unavailable / 13.32% |
| 2016-Q40/3 |
LoseNAMS / S&P NAMS unavailable / 3.82% |
LoseNAMS / S&P NAMS unavailable / 2.09% |
LoseNAMS / S&P NAMS unavailable / 7.05% |
| 2016-Q30/3 |
LoseNAMS / S&P NAMS unavailable / 3.85% |
LoseNAMS / S&P NAMS unavailable / 0.20% |
LoseNAMS / S&P NAMS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | NAMS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 7.65% | 20.78% |
| Annualized return | 7.65% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | NAMS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 163.38% | 83.14% |
| Annualized return | 21.37% | 12.86% |
10Y · 2021-02-09 to 2026-08-28
| Metric | NAMS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 143.97% | 319.30% |
| Annualized return | 9.33% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |